SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Akanda Corp. is a cannabis cultivation, manufacturing, and distribution company, which engages in the provision of premium quality and ethically sourced medical cannabis products to patients. The company cultivates and processes natural cannabis at facilities in the Kingdom of Lesotho, Africa and intend to supply medicinal-grade cannabis biomass, cannabis flower, and cannabis concentrates to wholesalers. It also imports and sells medical cannabis-based products. The company was founded on July 16, 2021 and is headquartered in New Romney, the United Kingdom.

Akanda Corp

Akanda Corp is experiencing extreme volatility driven by retail momentum and short-squeeze speculation on its low-float status, leading to frequent trading halts. While some investors see long-term potential in its telecom and cannabis operations, a vocal segment of the community remains skeptical, citing a history of reverse splits and dilution risks.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending as traders debate the impact of its regulatory approval in Singapore and anticipate upcoming quarterly earnings, with the community closely watching for updates on international expansion and product momentum. Sentiment remains divided, as some investors express frustration over price volatility and short-selling pressure, while others maintain a bullish outlook on the company's long-term transformation into a diversified global financial platform.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Joby Aviation is facing significant bearish pressure as investors grapple with dilution concerns, insider selling, and high cash burn, despite ongoing progress in FAA type certification and upcoming NYC test flight demonstrations. Community sentiment remains deeply divided between long-term bulls highlighting institutional backing from Toyota and Delta, and skeptical shorts who view the stock as overvalued and prone to further technical breakdowns.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Luxembourg.

Spotify Technology S.A.

Spotify is facing significant volatility as investors weigh strong platform metrics and record subscriber growth against concerns over slowing revenue momentum and weaker forward guidance. The community remains divided, with some traders viewing the current sell-off as an attractive entry point into a dominant market leader, while others caution that the stock faces valuation pressure and ongoing churn risks from recent subscription price hikes.

Erasca, Inc. is a clinical stage precision oncology company. It focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim and Kevan Shokat on July 2, 2018 and is headquartered in San Diego, CA.

Erasca Inc

Erasca is seeing significant volatility following the disclosure of a patient death in a clinical trial and a patent infringement letter from Revolution Medicines. While some investors remain optimistic about the company's potential as a best-in-class oncology play, the community is deeply divided between those buying the dip as a high-risk opportunity and others warning of potential bankruptcy and further downside due to the negative regulatory and legal developments.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the Advanced Technology Solutions (ATS) and Connectivity and Cloud Solutions (CCS) segments. The ATS segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The CCS segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

Celestica is currently experiencing significant downward pressure despite a strong earnings report and raised guidance, as investors react to the company's increased capital expenditures and broader cooling sentiment in the AI infrastructure sector. The community is actively debating whether this pullback represents a fundamental break in the growth story or a buying opportunity, with many traders focused on key support levels and the stock's tendency for sharp volatility around earnings events.

Centene Corp. is a healthcare enterprise, which engages in the provision of programs and services to government sponsored healthcare programs. It operates through the following segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment includes the Temporary Assistance for Needy Families program, Medicaid Expansion programs, the Aged, Blind or Disabled program, the Children's Health Insurance Program, Long-Term Services and Supports, Foster Care, Medicare-Medicaid Plans, which cover beneficiaries who are dually eligible for Medicaid and Medicare, and other state-based programs. The Medicare segment consists of Medicare Advantage, Medicare Supplement, Dual Eligible Special Needs Plans, and Medicare Prescription Drug Plans. The Commercial segment is involved in the Health Insurance Marketplace product along with individual, small group, and large group commercial health insurance products. The Other segment refers to pharmacy operations, Envolve Benefit Options’ vision and dental services, clinical healthcare, behavioral health, the TRICARE program, and corporate management companies. The company was founded in 1984 and is headquartered in St. Louis, MO.

Centene Corp.

Centene Corp. is experiencing volatility as investors closely monitor pending legislative votes regarding Affordable Care Act subsidy extensions, which remain a critical catalyst for healthcare plan providers. The community is actively debating the potential impact of this policy uncertainty against Centene's underlying operational resilience and its strategic focus on Medicaid and value-based care.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending as investors focus on the company's transformation into an AI infrastructure powerhouse, fueled by speculation regarding imminent hyperscaler contracts and the upcoming energization of its Sweetwater facility. While sentiment is divided between those frustrated by management's silence on new deals and those buying the dip, the community is heavily focused on the stock's potential for a significant re-rating as it pivots from bitcoin mining to high-performance computing.

Quantum BioPharma Ltd. is a biopharmaceutical company, which engages in building a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory, metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. It operates through the Biopharmaceutical and Strategic Investments segments. The Biopharmaceutical segment focuses on furthering the research and development of the drug candidates and the development of a treatment for alcohol misuse for application in hospitals and other medical practices. The Strategic Investments segment is involved in the generation of returns and cash flow through the issuance of loans secured by residential property, with FSD Strategic Investments having a first or second collateral mortgage on the secured property. The company was founded by Thomas Fairfull, Zeeshan Saeed, and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

Quantum BioPharma Ltd. - Ordinary Shares - Class B (Sub Voting)

Quantum BioPharma Ltd

Quantum BioPharma is trending as investors monitor ongoing legal battles regarding alleged stock manipulation and market spoofing, fueling high-stakes community debate about the company's long-term valuation and clinical prospects. Traders are actively discussing the stock's volatility and the potential impact of pending regulatory and legal milestones on its future market performance.

Rambus, Inc. engages in the provision of cutting-edge semiconductor and Internet Protocol products, spanning memory and interfaces to security, smart sensors and lighting. Its products include Memory Interface Chips, Interface IP, and Security IP. The company was founded by P. Michael Farmwald and Mark A. Horowitz in March 1990 and is headquartered in Sunnyvale, CA.

Rambus Inc.

Rambus is facing intense volatility as market participants react to mixed quarterly guidance, despite strong institutional backing and growth potential in the AI-driven data center sector. The community is actively debating whether the recent sharp pullback represents an attractive long-term entry point or a structural sign that the stocks valuation has become overextended.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Pfizer said on Tuesday that it has reached settlement agreements with three generic manufacturers — Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd. — resolving patent-infringement lawsuits over Vyndamax.&nbsp;</li><li>The deals, filed in U.S. District Court in Delaware, effectively push the U.S. patent exclusivity for Vyndamax to June 1, 2031.</li><li>Morgan Stanley said in a note that the Pfizer settlement is at the lower end of investors' expectations.</li></ul>Shares of BridgeBio (BBIO) fell 6% on Tuesday after rival Pfizer (PFE) reached a settlement with three generic drugmakers regarding its drug Vyndamax, which Wall Street deems at the lower end of expectations.BridgeBio is a primary competitor to Pfizer in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) market, following the FDA approval of BridgeBio's drug, Attruby, which challenges Vyndamax.PFE shares traded marginally in the red at the time of writing.<h2 class="st-heading-2">Pfizer’s Settlement</h2>Pfizer Inc. (PFE) said on Tuesday that it has reached settlement agreements with three generic manufacturers — Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd. — resolving patent-infringement lawsuits over Vyndamax.The deals, filed in U.S. District Court in Delaware, effectively push the U.S. patent exclusivity for Vyndamax to June 1, 2031, subject to the outcome of any remaining litigation. The agreements avert an earlier generic entry that Pfizer had anticipated would trigger a sharp drop in U.S. sales beginning in 2029.As a result, the company now expects Vyndamax revenues to remain relatively stable from 2028 through the middle of 2031.Vyndamax treats cardiomyopathy caused by transthyretin-mediated amyloidosis (ATTR-CM), a rare and often fatal heart condition. It holds about 75% of prescription volume in the ATTR-CM category.<h2 class="st-heading-2">Wall Street Weighs In</h2>Morgan Stanley said in a note that the Pfizer settlement is at the lower end of investors' expectations. The firm has an ‘Equal Weight’ rating and $28 price target on Pfizer shares.Mizuho and Barclays believe a "major overhang" has been removed on BBIO shares. However, Mizuho expected the terms to be favorable for Pfizer. The settlement is likely occurring somewhere in the 2033-2035 timeframe, implying BridgeBio could potentially trade into the $90-$110 range on the near-term, the analyst told investors in a research note prior to the deal details announcement.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around BBIO stock jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘high’ to ‘extremely high’ levels.Meanwhile, sentiment around PFE stayed within the ‘neutral’ territory while message volume remained at ‘high’ levels.A Stocktwits user highlighted that Pfizer still won the settlement deal. &nbsp;<stembedurl>https://www.stocktwits.com/Typecheck/message/651624210</stembedurl>Another said they added more BBIO shares in light of the dip.<stembedurl>https://www.stocktwits.com/sampeper/message/651638176</stembedurl>A third user termed BBIO a “screaming buy.”<stembedurl>https://www.stocktwits.com/MikeyNJ/message/651636900</stembedurl>While <a href="https://stocktwits.com/symbol/BBIO">BBIO stock</a> has gained 96% over the past 12 months, <a href="https://stocktwits.com/symbol/PFE">PFE</a> rose 15%. &nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/sngx-stock-52week-low-lymphoma-trial-fail/cZBobpeRedl">SNGX Stock Slumps To Record Low After Lymphoma Trial Fails – All Eyes Now On Behçet’s Disease Treatment</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the BridgeBio logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

BBIO On Track For Worst Day In 2.5 Months: What’s The Pfizer Connection?

BridgeBio is a primary competitor to Pfizer in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) market.

Equity

BridgeBio is a primary competitor to Pfizer in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) market.


BridgeBio Pharma (NASDAQ:BBIO) Shares Gap Up - Here's What Happened

BridgeBio Pharma (NASDAQ:BBIO) Shares Gap Up - What's Next...

BridgeBio Pharma (NASDAQ:BBIO) Earns "Outperform" Rating from Mizuho

Mizuho restated an "outperform" rating and set a $106.00 price target on shares of BridgeBio Pharma in a report on Tuesday...

BridgeBio Pharma (BBIO) Expected to Announce Earnings on Tuesday

BridgeBio Pharma (NASDAQ:BBIO) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 5. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-5-bridgebio-pharma-inc-stock...

Will BridgeBio Pharma (BBIO) Report Negative Q1 Earnings? What You Should Know

BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

HC Wainwright Reiterates Buy Rating for BridgeBio Pharma (NASDAQ:BBIO)

HC Wainwright reissued a "buy" rating and set a $100.00 price objective on shares of BridgeBio Pharma in a research report on Monday...

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) have been given an average recommendation of "Moderate Buy" by the twenty-five ratings firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and twenty-four h...

M&T Bank Corp Takes Position in BridgeBio Pharma, Inc. $BBIO

M&T Bank Corp purchased a new stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased...

BridgeBio Pharma (NASDAQ:BBIO) CEO Sells $2,984,800.00 in Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) CEO Neil Kumar sold 40,000 shares of the business's stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $74.62, for a total transaction of $2,984,800.00. Following the completion of the...

BridgeBio Pharma (NASDAQ:BBIO) Raised to "Moderate Buy" at Royal Bank Of Canada

Royal Bank Of Canada raised shares of BridgeBio Pharma to a "moderate buy" rating in a research report on Wednesday...

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Francis Patrick McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

BridgeBio Pharma Inc

Hold rates steady

Cut 25 bps

Hike 25 bps

What do you expect the Fed to decide at its FOMC meeting Wednesday?

Stocktwits

Stocktwits Polls

Investors are weighing the impact of patent litigation settlements on the long-term competitive landscape for heart disease treatments.

Wall Street firms remain optimistic with multiple reiterations of overweight ratings and aggressive price targets reaching as high as $160.

BBIO
BridgeBio Pharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest BBIO News

BBIOBridgeBio Pharma Inc